

Interferons for Multiple Sclerosis (MS)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Avonex (interferon beta-1a)	May be subject to quantity limit
Betaseron (interferon beta-1b)	
Extavia (interferon beta-1b)	
Plegridy (interferon beta-1a)	
Rebif (interferon beta-1a)	

APPROVAL CRITERIA

Requests for beta interferons [Avonex, Plegridy, Rebif (interferon beta-1a)] or [Betaseron, Extavia (interferon beta-1b)] may be approved if the following criteria are met:

- I. Individual has a diagnosis of relapsing multiple sclerosis (RMS) (including clinically isolated syndrome, relapsing-remitting disease or active secondary progressive disease).

Beta interferons [Avonex, Plegridy, Rebif (interferon beta-1a)] or [Betaseron, Extavia (interferon beta-1b)] may not be approved for the following:

- I. Individual is using to treat primary progressive multiple sclerosis (PPMS); **OR**
- II. Individual is using to treat non-active secondary progressive multiple sclerosis (SPMS); **OR**
- III. Use in combination with other MS disease modifying agents (including Aubagio, Avonex, Bafiertam, Betaseron, Copaxone/Glatiramer/Glatopa, Extavia, Gilenya, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Plegridy, Ponvory, Rebif, Tecfidera, Tysabri, Vumerity and Zeposia); **OR**
- IV. May not be approved when the above criteria are not met and for all other indications.

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 9, 2022.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.
4. Olek MJ, Howard J. Clinical presentation, course and prognosis of multiple sclerosis in adults. Last updated: May 9, 2022. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: July 10, 2022.
5. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2018; 90: 777-788. Available from: <https://www.aan.com/Guidelines/home/GuidelineDetail/898>. Accessed: July 7, 2022.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.